Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases

Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in China, exerts antiangiogenic and antineoplastic function through selectively binding and inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2). In this study, we aimed to explore the efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jianping, Liu, Xiaoyan, Yang, Sheng, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851530/
https://www.ncbi.nlm.nih.gov/pubmed/31610827
http://dx.doi.org/10.3727/096504019X15707896762251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851530/
https://www.ncbi.nlm.nih.gov/pubmed/31610827
http://dx.doi.org/10.3727/096504019X15707896762251

Ejemplares similares